Evidence map›Paper›PMID 40762658›Full record

ArticleWorld journal of urology2025

Can the contralateral systematic prostate biopsy be omitted in men with unilateral index lesion on MRI? A single-center retrospective study.

Yongsheng Nian, Qiuya Xu, Yongbing Cheng, Danyan Li, Li Zhu, Haifeng Huang, Yao Fu, Shan Peng, Hongqian Guo, Xuefeng Qiu

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yongsheng Nian *Department of Urology, Affiliated Hospital of Medical School, Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China.
Qiuya Xu *Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210009, China.
Yongbing Cheng *Department of Urology, Affiliated Hospital of Medical School, Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China.
Danyan Li *Department of Radiology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China.
Li ZhuDepartment of Pathology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China.
Haifeng HuangDepartment of Urology, Affiliated Hospital of Medical School, Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China.
Yao FuDepartment of Pathology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China.
Shan PengDepartment of Pathology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China.
Hongqian GuoDepartment of Urology, Affiliated Hospital of Medical School, Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China. dr.ghq@nju.edu.cn.
Xuefeng QiuDepartment of Urology, Affiliated Hospital of Medical School, Institute of Urology, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210009, China. Xuefeng_qiu@nju.edu.cn.

Funding

Nanjing Drum Tower Hospital Clinical Research Special Fund Cultivation Project (2022-LCYJ-PY-16Nanjing Drum Tower Hospital Clinical Research Special Funding Program 2023-LCYJ-MS-15National Natural Science Foundation of China 82172639
6 · The paper itself

Abstract

purposeThe objective of this study was to evaluate the diagnostic efficacy of combining prostate targeted biopsy (TB) with ipsilateral systematic biopsy (iSB) for men with unilateral index lesion on magnetic resonance imaging (MRI).

methodsThis single-center, retrospective study included 654 patients with unilateral index lesion (PI-RADS ≥ 3) on MRI who underwent prostate target biopsy combined with 12-core systematic biopsy (SB) between January 2022 to February 2023. The index lesion was defined as the lesion with the highest PI-RADS score or, in cases of multiple lesions with the same highest score, the one with the largest diameter. Ipsilateral systematic biopsy (iSB) was defined as the hemi-lateral systematic biopsy on the same side as the index lesion on MRI, while contralateral systematic biopsy (cSB) was defined as the hemi-lateral systematic biopsy on the opposite side. Kappa consistency analysis was conducted to compare the csPCa detection rates between TB combined with SB (TB + SB) and TB combined with iSB (TB + iSB). The McNemar test was used to compare the csPCa detection rates between TB + iSB and TB + cSB.

resultsThe csPCa detection rate was higher for TB + iSB than for TB + cSB (44.87% vs. 42.73%, P < 0.01). TB + iSB showed greater consistency with TB + SB than TB + cSB (K = 0.975 vs. 0.932). Stratified analysis revealed similar results across PI-RADS scores, PSA levels (< 20 ng/ml), age, and prostate volumes, except for PSA levels > 20 ng/ml (66.67% vs. 68.9%, P < 0.01).

conclusionTB + iSB, which omits half of the SB cores, demonstrates extremely high consistency with TB + SB in detecting csPCa in men with unilateral index lesion on MRI, and has a higher csPCa detection rate compared to TB + cSB, indicating its potential to replace TB + SB.

Indexed as

Image-Guided BiopsyProstateProstatic NeoplasmsUnnecessary ProceduresAgedDiffusion Magnetic Resonance ImagingHumansMaleMiddle AgedRetrospective StudiesContralateral systematic biopsyIpsilateral systematic biopsyProstate cancerTarget biopsyUnilateral systematic biopsy

Identifiers

PMID40762658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.